Vitasora HealthASX:VHL ROE % is -64.77% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 626 Healthcare Providers & Services companies, Vitasora Health ranks worse than 93.45% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Vitasora Health's annualized net income for the quarter that ended in Dec. 2025 was A$-10.26 Mil. Vitasora Health's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was A$15.84 Mil. Therefore, Vitasora Health's annualized ROE % for the quarter that ended in Dec. 2025 was -64.77%.
The historical rank and industry rank for Vitasora Health's ROE % or its related term are showing as below:
ASX:VHL'
s ROE % Range Over the Past 10 Years
Min: -16977.27 Med: -202.67 Max: -86.46
Current: -95.32
During the past 13 years, Vitasora Health's highest ROE % was -86.46%. The lowest was -16,977.27%. And the median was -202.67%.
ASX:VHL's ROE % is ranked worse than 93.45% of 626
companies
in the Healthcare Providers & Services industry
Industry Median: 5.805
vs ASX:VHL: -95.32
Vitasora Health (ASX:VHL) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Vitasora Health ROE % Related Terms
Vitasora Health ROE % Historical Data
* Premium members only.
The historical data trend for Vitasora Health's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Vitasora Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitasora Health ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Vitasora Health's ROE % distribution charts can be found below:
* The bar in red indicates where Vitasora Health's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Vitasora Health (ASX:VHL) has a ROE % of -64.77% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vitasora Health and its competitors. According to the industry distribution chart, Vitasora Health ranks #585 out of 626 companies in the Healthcare Providers & Services industry, placing it in the top 93.5%.
Is Vitasora Health's ROE % too high?
Vitasora Health's current ROE % is -64.77%. Based on the distribution chart, Vitasora Health ranks #585 out of 626 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Vitasora Health's ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Vitasora Health ranks #585 out of 626 companies for ROE %. This places Vitasora Health in the lower half of its industry. The industry median ROE % is 5.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.81, based on 626 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vitasora Health and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitasora Health's current ROE % is -64.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitasora Health stock overvalued right now?
Vitasora Health (ASX:VHL) has a current ROE % of -64.77%. The current ROE % is -64.77%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Vitasora Health (ASX:VHL), the current ROE % is -64.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitasora Health Ltd is engaged in healthcare technology and services, providing critical patient health tracking services to clinicians and healthcare teams. Through data-driven programs, clinical technology, and support tools, it enables healthcare professionals to extend the capacity of care beyond the clinic. The company operates in Australia and the USA, with the majority of its revenue coming from the USA. The United States reportable segment, through the acquisition of Access Telehealth and Orb Health, provides reportable segment activities such as a broader value proposition and solutions for managing the majority chronic disease states, including Cardiovascular, Diabetes, Chronic Obstructive Pulmonary Disease (COPD), and Obesity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VHL has been successfully added to your 